The Global Cancer Immunotherapy Market has been valued at US$ 96.5 billion by 2023, and will be valued at US$ 228.5 billion by 2032, with a CAGR of 10.05% between 2024 and 2032. The factors that will aid in the development of this market are: enhance expenditure on healthcare, emergence in the occurrence of cancer, rise in availability of medical insurance, and advancement in the technologies implemented in cancer treatment therapies.
Cancer immunotherapy looks very promising in treatment of many types of cancer and its application has recently increased enormously, many clinical trials are currently running worldwide. Several immunotherapy drugs have been approved in the USA and Europe and are currently considered as the first-line therapy for some types of cancer. Nevertheless, access to, as well as the price of, creative work remains an issue in many locations. Researchers and practitioners are developing new treatments with multiple immunotherapy agents, individual patient treatments, and ways to overcome immunotherapy resistance.
Also, growth in the number of new approvals and the launch of high-quality products for cancer treatment also influences the growth of the market. For example, AstraZeneca India’s Lynparza (Olaparib) was approved to act as an adjuvant treatment for particular kinds of breast cancer in adults. At the same time, Roche Pharma introduced PHESGO as a new treatment for HER2-positive breast cancer. Altogether, these factors point to considerable growth potential for the Asia-Pacific cancer therapy market in the years ahead.
Cancer Immunotherapy Overview
Immunotherapy for cancer employs the immune system of the body to fight cancer. Immunologic enhancement is another area in which it aids in the identification and destruction of malignant cells by the immune system. Examples include checkpoint inhibitors, CAR T-cell therapy, and cancer vaccines.Cancer immunotherapy looks very promising in treatment of many types of cancer and its application has recently increased enormously, many clinical trials are currently running worldwide. Several immunotherapy drugs have been approved in the USA and Europe and are currently considered as the first-line therapy for some types of cancer. Nevertheless, access to, as well as the price of, creative work remains an issue in many locations. Researchers and practitioners are developing new treatments with multiple immunotherapy agents, individual patient treatments, and ways to overcome immunotherapy resistance.
Growth Factors in the Cancer Immunotherapy Industry
Rising Incidence of Cancer
The global cancer incidences rising over the years is a major driver of the global cancer immunotherapy market. Different types of cancer are increasingly being diagnosed and recorded across the globe especially with aging populations and areas with high risk factors such as smoking and pollution; therefore, there is the need to increase drug efficacy and specificity. Immunotherapy is much more efficient than traditional treatments such as chemotherapy, and radiation because it involves the activation of the immune system against cancer cells. The willingness of healthcare providers and patients to adopt immunotherapy for better survival and quality of life has heightened leading to increased demand and hence market growth. Global incidence of new cancer cases is expected to increase to 35 million in 2050, an increase of 77% from the current estimated 20 million in 2022. Population aging, population growth, and altering in people’s exposure to risk factors are some significant causes, which are associated with the process of socioeconomic development.Advancements in Immunotherapy Technologies
Technological trends are seen as one of the major forces that will shape the cancer immunotherapy market in the near future. Checkpoint inhibitors, CAR T cell therapy and personalized cancer vaccines are among the break through that have drastically changed cancer since patients are now able to get more effective treatments. These advanced treatments attack cancer cells while leaving the normal cells, thus fewer side effects, and a better quality of life in patients. Immunotherapy has also grown phenomenally and has continued to be researched, so more targets and treatment methods have been realized, which have widened the cancer types that can be addressed using immunotherapy. Since technology is continually enhancing, it will be possible to gain more and effective cancer immunotherapy to boost the market progress further.Increased Investment and Collaboration
Cancer immunotherapy industry is gaining a lot due to an increase in investment and strategic partnership in the biopharmaceutical sector. Major pharmaceuticals, biotechnology companies and research organizations are devoting more of their resources on research and development of latest immunotherapeutic products and solutions. Significant financing from both sides of the business world and the government backs this increase, acknowledging the capacity of immunotherapy in altering the cannonade of malignant neoplasms. Contemporary business and university partnerships are progressing patient studies and the regulatory process for startups. The immunotherapy drug market is still in a developing stage although more drugs are in the market and has shown promising results and due to this many players and investors are likely to venture in the industry hence driving the market. Tagrisso (osimertinib) developed by AstraZeneca has been launched in Republic of China to be used in 1st-line treatment of adult patients with locally advanced or metastatic NSCLC with an EGFR mutation. This approval covers the employment of pemetrexed and platinum-based therapy for patients with particular mutations in their tumors.Asia Pacific Cancer Immunotherapy Market Overview
The Asia-Pacific market for cancer therapy is expected to show a strong development in the future, due to the rising amount of cancer incidence, informational campaigns conducted by the governments, as well as patient support programs. In Asia-Pacific lung, stomach, colorectal, liver, and esophageal cancers are common. For instance, a piece called “Burden of cancers in India” estimated that the cancer burden in India is 26.7 million disability adjusted life years (DALYs) in 2021 and is estimated to rise as high as 29.8 million in 2025. This growing incidence and burden of cancer is a very key factor that is pressuring the market to grow.Also, growth in the number of new approvals and the launch of high-quality products for cancer treatment also influences the growth of the market. For example, AstraZeneca India’s Lynparza (Olaparib) was approved to act as an adjuvant treatment for particular kinds of breast cancer in adults. At the same time, Roche Pharma introduced PHESGO as a new treatment for HER2-positive breast cancer. Altogether, these factors point to considerable growth potential for the Asia-Pacific cancer therapy market in the years ahead.
Cancer Immunotherapy Market Company Overview
The leading companies in the global cancer immunotherapy market are Amgen Inc., AstraZeneca, Bayer AG, Bristol-Myers Squibb Company, Pfizer Inc., Novartis AG, Johnson & Johnson, Eli Lilly and Company, and Seattle Genetics Inc.Cancer Immunotherapy Market News
The US FDA authorized FRUZAQLA (fruquintinib) for Takeda's previously treated metastatic colorectal cancer in December 2023.- In October 2023, The U.S. Food and Drug Administration (FDA) approved Merck's anti-PD-1 drug KEYTRUDA as neoadjuvant and adjuvant treatment after surgery for resectable non-small cell lung cancer (NSCLC) patients.
- In October 2023, The U.S. Food and Drug Administration (FDA) authorized Pfizer's MEKTOVI (binimetinib) + BRAFTOVI (encorafenib) combination for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) who have a BRAF V600E mutation as identified by an FDA-approved test.
Products - Market breakup in 3 viewpoints:
- Monoclonal Antibodies
- Immunomodulators
- Cancer Vaccines
Application - Market breakup in 7 viewpoints:
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Melanoma
- Prostate Cancer
- Head & Neck Cancer
- Others
End User - Market breakup in 3 viewpoints:
- Hospital
- Cancer Research Center
- Clinics
Country - Market breakup in 25 viewpoints:
North America
- United States
- Canada
Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Switzerland
Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Indonesia
Latin America
- Brazil
- Argentina
- Mexico
Middle East & Africa
- South Africa
- Saudi Arabia
- United Arab Emirates
Rest of the World
The key players have been covered from 4 viewpoints:
- Overviews
- Key Person
- Recent Developments & Strategies
- Product Portfolio & Product Launch in Last 1 Year
- Revenue
Company Analysis:
- Amgen Inc.
- AstraZeneca
- Bayer AG
- Bristol-Myers Squibb Company
- Pfizer Inc
- Novartis AG
- Johnson & Johnson
- Eli Lily Company
- Seattle Genetics Inc
Table of Contents
1. Introduction2. Research Methodology3. Executive Summary5. Global Cancer Immunotherapy Market
4. Market Dynamics
6. Market Share Analysis
7. By Products
8. By Application
9. By End Users
10. By Countries
11. Porter’s Five Forces Analysis
12. SWOT Analysis
13. Key Players
Companies Mentioned
- Amgen Inc.
- AstraZeneca
- Bayer AG
- Bristol-Myers Squibb Company
- Pfizer Inc
- Novartis AG
- Johnson & Johnson
- Eli Lily Company
- Seattle Genetics Inc
Methodology
In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.
Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.
Primary Research
The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:
- Validates and improves the data quality and strengthens research proceeds
- Further develop the analyst team’s market understanding and expertise
- Supplies authentic information about market size, share, growth, and forecast
The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:
- Chief executives and VPs of leading corporations specific to the industry
- Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
- Key opinion leaders (KOLs)
Secondary Research
The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Patent and regulatory databases for understanding of technical & legal developments
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic new articles, webcasts, and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | August 2024 |
| Forecast Period | 2023 - 2032 |
| Estimated Market Value ( USD | $ 96.5 Billion |
| Forecasted Market Value ( USD | $ 228.5 Billion |
| Compound Annual Growth Rate | 10.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 9 |
